Nebulizers Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

 According to MRFR analysis, the Global Nebulizers Market is expected to register a CAGR of 7.32% during the forecast period of 2020 to 2027 and reach USD 1,629.7 Million by 2027.

A nebulizer is a type of breathing machine that is used to take inhaled medicines. Nebulizer treatment is carried out with an air compressor machine.

The growth of the global nebulizers market can be contributed to the growing need for rescue medication, high demand for respiratory devices, including nebulizers, due to outbreak of COVID-19 globally, and increasing prevalence of chronic respiratory diseases. According to a press release from Icon Plc in April 2020, the demand for respiratory devices has enormously increased, due to the rising cases of COVID-19.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/9586 

Furthermore, the growing demand for home healthcare devices, rising geriatric population, increasing consumption of alcohol, tobacco, cigarettes, and other such products that might lead to respiratory diseases, are also expected to fuel the market growth during the forecast period.

However, the loss of drug during nebulization procedures, availability of various substitutes for nebulizers, and side effects of nebulizer solutions are expected to restrain the growth of the global nebulizers market.

Several market players such as OMRON Healthcare, Koninklijke Philips N.V., and B. Braun Melsungen AG, among others currently dominate the global nebulizers market. The key players are involved in awareness campaigns, product approvals, mergers, and strategic collaborations to strengthen their market positions. For instance, in April 2020, B. Braun Melsungen AG received the Food and Drugs Administration (FDA) emergency use authorization for using its infusion pumps with nebulizers to treat COVID-19 patients.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas region held the largest market in 2019, owing to the rising demand for respiratory diseases in the region. The nebulizers market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European nebulizers market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The nebulizers market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing incidence rate of respiratory diseases, the market in Asia-Pacific is expected to be the fastest-growing. The nebulizers market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global Nebulizers Market has been Segmented Based on the Type, Usage, Portability, and End User.

Based on the Type, the global nebulizers market has been segmented into mesh, jet, and ultrasonic. The mesh segment is further divided into active and passive. The jet segment is expected to hold the largest market share owing to its low cost as compared to other types of nebulizers.

On the basis of usage, the market has been segmented into reusable and disposable. The disposable nebulizers are expected to hold a major market share owing to their growing popularity amongst the users.

Based on the portability, the market has been segmented into tabletop and portable. The portable nebulizers market is expected to grow at the fastest CAGR owing to its ease and convenience of use.

The market based on end-user has been segmented into hospitals & clinics, home care, and others. The hospitals and clinics segment is expected to hold the largest market share owing to the larger patient footfall in hospitals.

Key Players

Some of the key players in the global nebulizers market are OMRON Healthcare (Japan), Koninklijke Philips N.V. (Netherlands), PARI (US), Vectura Group plc (UK), Rossmax International Ltd (Taiwan), Briggs Healthcare (US), GF Health Products, Inc. (US), Beurer GmBH (Germany), Agilent Technologies, Inc. (US), Drive DeVilbiss Healthcare (US), Invacare Corporation (US), and B. Braun Melsungen AG (Germany).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nebulizers-market-9586 

Global Electronic Trial Master File (eTMF) Systems Market Show Steady Growth: Study 2027

 According to MRFR analysis, Global eTMF Systems Market is expected to register a CAGR of 13.11% during the forecast period of 2019 to 2025 and anticipated to reach USD 1,825 Million by 2025.

The eTMF serves as a central repository to store and manage essential clinical trial documents and content for possible use in regulatory submissions. The eTMF software streamlines agency compliance with standards-based exports, and eSubmissions enables sharing between clinical trial stakeholders with language-independent taxonomy.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8772 

The growth of the global eTMF systems market is fueled by several factors such as rising activities in terms of acquisitions, new solution and service deployments, and collaborations by key players operating in the market, coupled with the increasing number of clinical trial studies. For instance, in October 2019, SureClinical Inc. launched a transparent eTMF pricing policy. To provide value to the prospective users, the company has posted its prices and terms online to battle price discrimination in this industry. However, budget constraints of the small and medium-sized enterprises, along with the dearth of skilled professionals for operating the electronic systems, can hinder the preference of such solutions. As a result, such elements can hamper the growth of the market during the forecast period.

Several market players currently dominate the global eTMF systems market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in June 2018, Phlexglobal, a UK-based specialist provider of TMF and eTMF management solutions, is adopting Version 1 of the eTMF Exchange Mechanism Standard (eTMF-EMS) of the TMF Reference Model (TMF-RM) into PhlexEview, the company’s eTMF technology. Such strategies push the growth of the eTMF systems market.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas held the maximum share in the base year 2018, owing to the presence of established key players in countries such as the US and Canada. The eTMF systems market in the Americas has been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European eTMF systems market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The eTMF systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The eTMF systems market in this region is anticipated to be the fastest-growing during the assessment period due to the increased adoption rate of eTMF software and services in the Asian countries. The eTMF systems market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global eTMF Systems Market has been segmented based on Component, Deployment Mode, and End User.

The global eTMF systems market has been segmented, based on the component, into software and services. The software segment is expected to hold the majority share of the market owing to the increasing number of solution launches by the prominent players in recent years. The services segment is expected to be the fastest-growing due to the increasing uptake of eTMF services by pharmaceutical and life science companies.

The global eTMF systems market, based on deployment model, has been segmented into cloud/web-based, and on-premise. The cloud/web-based segment holds the maximum share owing to the technological advancements in cloud-based solutions in recent years.

The end-users of the market are pharmaceutical and biotechnology companies, contract research organizations, and others. The increasing number of clinical trials conducted by pharma firms is leading to the market size of the pharmaceutical and biotechnology companies’ segment.

Key Players

Some of the Key Players in the Global eTMF Systems Market are Aurea, Inc. (US), Covance Inc. (US), ePharmaSolutions (US), MasterControl, Inc. (US), Oracle (US), Phlexglobal (UK), SureClinical Inc. (US), TransPerfect (US), Veeva Systems (US), and Wingspan (IQVIA) (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/etmf-systems-market-8772 

Avian Influenza Vaccine Market Dynamics, Segments and Supply Demand 2020-2027

 Global Avian Influenza Vaccine Market is expected to register a CAGR of 7.25% during the forecast period, with a market value of USD 735.22 Million till 2025. Avian influenza or bird flu is an infection caused in birds due to the influenza type A virus. These viruses naturally occur among wild aquatic birds and can easily infect domestic poultry, other birds, and animal species.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8769 

Segment Analysis

The Global Avian Influenza Vaccine Market has been segmented by strain and application. The market, based on strain, has been bifurcated into H5, H7, and H9. Based on the application, the avian influenza vaccine market has been segregated into chicken, turkey, duck, and goose.

Regional Analysis

The Global Avian Influenza Vaccine Market, based on region, has been divided into the APAC & Middle East, Europe, Americas, and Africa.

The APAC & Middle East is likely to dominate the global avian influenza vaccine market. This can be attributed to the rise in avian influenza outbreaks and various government initiatives for the rapid and effective management of avian influenza in the region. According to a research study published in BioMedCentral in 2018, China, Vietnam, India, Taiwan, Israel, Japan, and South Korea have reported some of the largest outbreaks during the period of 2010–2016. Of these, the highest outbreaks were located in China (13.6%) in 2016. Moreover, high R&D expenditure invested by numerous key market players in the Asia-Pacific region is also expected to drive market growth.

The European market for the avian influenza vaccine is expected to be the second-largest during the review period. The collaborative initiatives of the government and private entities to promote improved animal health are expected to boost the growth of the regional market. For instance, the EU is working closely together with the World Health Organization, the Food and Agriculture Organization and the World Organization for Animal Health (OIE), in response to the global threat of avian flu. Additionally, the increasing production of veterinary products is also fueling market growth.

The Americas are estimated to be the fastest-growing market owing to the huge amount of animal welfare and veterinary/animal vaccine research-related activities in the region. For instance, the USGS Alaska Science Center has been a part of the State and Federal interagency team for the detection and response to highly pathogenic (HPAI) viruses in North America. Moreover, growing government support for creating awareness on avian influenza viruses and improving efficiency for the avian influenza vaccine is also positively affecting the market growth.

The market in Africa is expected to witness the lowest growth due to the limited access and availability of the avian influenza vaccine.

Key Findings of the Study

• The Global Avian Influenza Vaccine Market is estimated to reach USD 735.22 Million by 2025 at a CAGR of 7.25% during the assessment period

• The APAC & Middle East accounted for the largest share of the global avian influenza vaccine market due to the increasing prevalence of avian influenza

• Based on strain, the H5 segment accounted for the largest market share of 62.5% in 2018

• Based on application, the chicken segment accounted for the largest market share of 36.1% in 2018

Key Players

MRFR recognizes the following companies as the Key Players in the Global Avian Influenza Vaccine Market— Boehringer Ingelheim International GmbH (Germany), Guangdong Wenshi Dahuanong Biotechnology Co., Ltd (China), Ceva (US), Yebio Bioengineering Co., Ltd (China), Zoetis (US), FATRO S.P.A. (Italy), CAVAC (South Korea), Tianjin Ringpu Bio-Technology Co., Ltd (China), PT Japfa Comfeed Indonesia Tbk (Indonesia), Chengdu Tech-bank Biological Products Co., Ltd (China), Merck Animal Health (US), Medion (Indonesia), Avimex Animal Health (Mexico), JOVAC (Jordan), and QYH BIOTECH COMPANY LIMITED (China).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/avian-influenza-vaccine-market-8769 

Interventional Cardiology Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

 Global Interventional Cardiology Market held a value of USD 15,130.75 Million in 2018 and is expected to register a CAGR of 7.25% during the assessment period of 2019 to 2025.

Interventional cardiology deals with the catheter-based treatment of heart diseases. Scrutinizing all the global territories, it has been noticed that there is a huge rise in the number of cardiac diseases. This can be attributed to the change in lifestyle, leading to lifestyle diseases. Each year cardiovascular diseases cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8735

Many market players are dominating the global interventional cardiology market. The prominent players are involved in strategic agreements, product launches, and joint ventures to brace their market positions. For instance, in May 2018, Terumo Europe NV announced the launch of Ultimate Tensei drug-eluting stent in Europe.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas held maximum share in the base year 2018, owing to the high incidence rates of cardiac disorders and strategic activities by major players in countries such as the US. The interventional cardiology market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European interventional cardiology market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The European market for interventional cardiology is expected to hold a substantial share owing to the increase in the number of cardiac disorder cases. For instance, in 2016, there were 66,076 deaths due to coronary heart diseases in the UK, which was the third-highest cause of death in that particular year. The interventional cardiology market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The interventional cardiology market in this region is anticipated to be the fastest-growing during the forecast period due to the increasing uptake and adoption rate of newer treatment options by patients as well as medical professionals. The increasing patient pool and mortality rate due to cardiac diseases in these countries also fuel the market growth. For instance, in 2017, ischemic heart disease was the second-highest cause for death in Japan. The interventional cardiology market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global Interventional Cardiology Market has been segmented based on Type, and End User.

The market, based on type, has been segmented into stents, percutaneous transluminal coronary angioplasty (PTCA) catheters, plaque modification devices, coronary guidewires, and accessories. The market, based on stents, has been further divided into drug-eluting stents, bare-metal stents, and bioresorbable vascular scaffolds. The stents segment held a major share in 2018 owing to the increased number of product launches by key players in the current years. This segment is also expected to be the fastest-growing segment during the forecast period due to the increasing prevalence of coronary artery disease, and continued innovations by players. The market, based on PTCA catheters, has been segmented into balloon catheters, and guiding catheters.

The Global Interventional Cardiology Market has been segmented, based on end-user, into hospitals, cardiac catheterization laboratories, ambulatory surgical centers, and others. In 2018, the hospital’s segment held the majority share of the market owing to the increasing number of patient admissions due to coronary diseases. The cardiac catheterization laboratory segment is projected to be the fastest-growing segment owing to the increasing preference of cath labs by medical professionals.

Key Players

Some of the Key Players in the Global Interventional Cardiology Market are ABIOMED (US), Abbott (US), ACIST Medical Systems, Inc. (the US), B. Braun Melsungen AG (Germany), BD (US), Biosense Webster, Inc (US), Biotronik SE & Co. KG (Germany), Boston Scientific Corporation (US), Cardinal Health (US), Cook Medical (US), Edwards Lifesciences Corporation (US), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Life Vascular Devices Biotech S.L. (Spain), Medtronic (Ireland), Merit Medical Systems, Inc (US), Terumo Corporation (Japan), and W. L. Gore & Associates, Inc. (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/interventional-cardiology-market-8735

Influenza Vaccines Market: Comprehensive Analysis of Factors That Drive Influenza Vaccines Market Growth (2020 - 2027)

 Global Influenza Vaccines Market is expected to register a CAGR of 6.53% to reach USD 7,828.3 Million by 2025. Influenza viruses are one of the major infectious disease threats to the human population. Vaccination is the major public health measure for the prevention of influenza virus infection. Influenza vaccines are also known as flu shots or flu jabs. Currently available seasonal influenza vaccines are either trivalent or quadrivalent in composition.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1621

Market Dynamics

Influenza is an infection of the upper airway caused by an influenza virus, which is commonly known as flu. The most common symptoms include high fever, sore throat, headache, coughing, and sneezing. In 2018, 69,007 people were diagnosed with influenza viruses, out of which 67,733 were diagnosed with the influenza A virus and 1,274 with the influenza B virus, respectively. Moreover, influenza has resulted in between 9.3 million to 49.0 million cases of illnesses since 2010 in the US alone. This surge in influenza epidemics raises the demand for influenza vaccines, thereby contributing to the growth of the global influenza vaccines market. Moreover, increasing public & private initiatives for research & development of influenza vaccine, growing awareness about influenza vaccines, and increasing product launches & approvals

Segmentation

The Global Influenza Vaccines Market has been segmented by influenza Type, Manufacturing Technology, Vaccine Type, and End User.

The market, based on influenza type, has been bifurcated into seasonal and zoonotic. Based on manufacturing technology, the global influenza vaccines market has been bifurcated into egg-based, cell culture-based, and recombinant-based. On the basis of vaccine type, the global influenza vaccines market has been bifurcated into trivalent vaccines and quadrivalent vaccines. Based on end user, the global influenza vaccines market has been classified as hospitals and clinics, research organizations and academic institutions, and others.

Regional Analysis

The Global Influenza Vaccines Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is likely to dominate the global influenza vaccines market. This can be attributed to the rising prevalence of influenza in the region. Each year on average, 5% to 20% of the US population suffers from influenza. Furthermore, there are approximately 31.4 million outpatient visits due to influenza and more than 200,000 hospitalizations each year. This surge in influenza would support market growth in the American region.

The European market for influenza vaccines is expected to be the second largest during the review period. The high prevalence of seasonal influenza and the rise in product launches by key players is expected to boost the growth of the regional market. Moreover, the influenza vaccine uptake has increased to 72% from 2018 to 2019, from 70.5% from 2016 to 2017. This rising demand for influenza vaccines is anticipated to drive the market growth in this region.

The market in Asia-Pacific is expected to register a significant growth rate during the forecast period owing to the rising investment by major companies to enhance their foothold in the regional market. For instance, in April 2017, Serum Institute of India Pvt Ltd acquired the Czech arm of the US-based, firm Nanotherapeutics for about USD 78 million (EUR 72 million) as a part of its growth strategy.

The market in the Middle East & Africa is likely to exhibit the lowest growth owing to the limited access and availability of treatment facilities. The developing healthcare infrastructure, and continuously increasing demand for vaccination are factors expected to drive the growth of the market in the region.

Key Players

The Prominent Players in the Global Influenza Vaccines Market are AstraZeneca (UK), GlaxoSmithKline PLC (UK), Sanofi (France), Abbott Laboratories (US), Seqirus (UK), Hualan Biological Engineering Inc. (China), Mitsubishi Tanabe Pharma (Japan), Serum Institute of India Pvt. Ltd (India), and Mylan NV (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/influenza-vaccination-market-1621

Research report covers the Primary Cells Market Forecasts and Growth, 2020-2027

 Primary Cells Market is expected to register a CAGR of 8.13% to reach USD 1,233.67 Million till 2025.

Primary human cells are isolated directly from normal human tissue or blood cells via the enzymatic or mechanical method. Primary cells retain their fundamental cellular functions. Hence, their use in cell-based research programs is increasing significantly.

Key factors that drive the primary cells market are the rapid growth in the biotechnology and biopharmaceutical industries, growing cancer research, rising adoption of primary cells over cell lines, increasing demand for monoclonal antibodies, and increasing healthcare expenditure are anticipated to drive the growth of the market during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6296

However, factors such as the high cost of advanced primary cells, and the risk of contamination may hamper the growth of the market. The increasing preference of primary cells in research and development to develop new drug acts as opportunities for the growth of the primary cells market.

Market Dynamics

Growing cancer research across the world demand. Cancer is one of the major causes of death across the globe and is responsible for a large number of deaths. Different pharmaceutical companies and research institutes are involved in developing cancer treatment drugs using cell culture. The increasing prevalence of cancer across the globe is promoting the demand for research activities to develop new drugs. According to the National Cancer Institute in 2018, around 1,735,350 cases of cancer were diagnosed in the US alone.

Additionally, Cancer Research UK reported that in 2018 the new cases of cancer were reported to be 17 million across the world. The increasing number of populations suffering from cancer increases the demand for new research activities to develop new drugs, which ultimately increases the demand for products such as primary cell culture. For instance, the National Cancer Institute conducts different research on cancer biology, cancer genomics, and causes of cancer using primary cell culture. Additionally, there are different major and small manufacturers and suppliers, such as Merck KGaA and PromoCell GmbH, who provide primary cells for cancer research.

Segmentation

The Global Primary Cells Market is segmented into source, Type, and End User. By source, the market has been segmented into hematopoietic cells, skin cells, gastrointestinal cells, liver cells, lung cells, and skeletal and muscle cells.

Based on type, the market has been segmented into human primary cells and animal primary cells. On the basis of end user, the market has been segmented into pharmaceutical and biotechnology companies and research institutes.

Regional Analysis

The Global Primary Cells Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to hold the largest share of the global primary cells market. The market growth in this region is attributed to the presence of a well-established healthcare system, increasing prevalence of cancer, growing government funding in research, and technological advancements. According to the National Cancer Institute, around 1,685,210 new cases of cancer were diagnosed in the US in 2016. A huge patient pool with cancer is thus driving the growth of the market. Increasing healthcare expenditure by government organizations to provide a better life to the people drives the market growth. For instance, in 2017, the healthcare expenditure in the US was USD 3.5 trillion, and this expenditure increased to USD 3.65 Trillion in 2018.

Europe is expected to account for the second-largest market share during the forecast period. The European market is segmented into Germany, the UK, Italy, Spain, France, and the rest of Europe. Europe held a healthy share in the global primary cells market and is the second-largest market leader after the Americas, owing to the presence of favorable government initiatives & laws, rising prevalence of lifestyle-associated conditions, and the presence of developed economies such as Germany, the UK, and France. According to the Office for National Statistics, the gross domestic expenditure on research and development (R&D) activities was EUR 33.1 billion (USD 35.2 billion) in 2016. The increased spending on research and development activity boosts the market growth in this region.

Asia-Pacific is projected to exhibit the fastest market growth from 2019 to 2025 owing to the increasing per capita health spending, growing geriatric population base, and developing the healthcare sector in China, Japan, India, and Australia. According to the World Bank, the healthcare expenditure in India for the year 2016 was 3.66.% of the total GDP (gross domestic product).

The market in the Middle East and Africa is expected to hold the least market share owing to limited access to treatment facilities. However, the increasing invests by healthcare companies in countries such as Saudi Arabia and the launch of new products will help to strengthen the market growth.

Key Players

The Prominent Players in the Global Primary Cells Market are AllCells (US), American Type Culture Collection (ATCC) ( Virginia), Axol Bioscience Ltd (UK), Cell Biologics, Inc. (Chicago), Lonza Group, AG (Switzerland), Merck KGaA (Germany), PromoCell (UK), STEMCELL Technologies Inc. (Canada), ZenBio, Inc. (Research Triangle Park, NC), Thermo Fisher Scientific Inc. (US), and among others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/primary-cells-market-6296

Nephrectomy Market: Comprehensive Analysis of Factors That Drive Nephrectomy Market Growth (2020 - 2027)

 Nephrectomy Market is expected to register a CAGR of 4.80% and was valued at USD 4,470.17 Million in 2018.

Nephrectomy is a surgical procedure performed to remove the kidney or a part of it. Nephrectomy is of two types, namely, radical nephrectomy in which the entire kidney is removed and partial nephrectomy where a part of the kidney or the diseased tissues is removed as a process of the treatment. Most frequently, a nephrectomy is done to treat kidney cancer or to remove a noncancerous tumor during urological surgery. The demand for nephrectomy is increasing due to the increasing prevalence of kidney cancer and chronic kidney diseases, the rising number of laparoscopic nephrectomy procedures, and increasing awareness about organ (kidney) transplant. These factors are expected to fuel the growth of the global nephrectomy market. However, risks and complications of the nephrectomy surgery and high cost of the procedure are anticipated to hamper the market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5356

Market Dynamics

Kidney cancer is a disease in which the healthy cells of one or both kidneys start proliferating in an uncontrolled manner and form lumps (called a tumor). In chronic kidney disease (CKD), also known as chronic renal disease, chronic renal failure, or chronic kidney failure, the problems are kidney-related that result to cause slow and progressive loss of kidney function over a period and eventually results in permanent kidney failure. The main causes of kidney diseases are diabetes and high blood pressure.

For instance, the National Kidney Foundation, Inc. reported that chronic kidney disease (CKD) is one of the leading causes of death in the US and also stated that around 75% of kidney failure was caused due to diabetes and high blood pressure between 2014 and 2016. According to the World Health Organization 2018 fact sheet, 422 million people were reported to have diabetes in 2014 across the world. The increasing prevalence of diabetes is leading to cause kidney problems and is thus driving the nephrectomy market.

Similarly, the awareness and demand for organ (kidney) transplant is likely to drive the market growth. According to the US Government Information on Organ Donation and Transplantation, 21,167 kidney transplants took place in 2018 in the US. Hence the demand for organ transplants is fueling the growth of the worldwide nephrectomy market.

Segmentation

The Global Nephrectomy Market has been divided based on procedure, indication, end-user, and region. The market, based on procedure, has been segregated into open nephrectomy, laparoscopic nephrectomy, and robot-assisted laparoscopic surgery. Based on indication, the nephrectomy market has been divided into kidney cancer and other kidney diseases. On the basis of end-user, it is bifurcated into hospitals & clinics, surgical centers, and others.

Regional Analysis

The Global Nephrectomy Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Rest of the World (RoW). The Americas are likely to dominate the global nephrectomy market. The increasing prevalence of kidney cancer in the region, high prevalence of chronic kidney diseases, and growing development in diagnostics would drive the growth of the nephrectomy market in this region. Moreover, according to the American Cancer Society, it is estimated that about 73,820 new cases of kidney cancer (44,120 in men and 29,700 in women) are likely to occur in 2019. Also, kidney cancer is among the ten most common cancers in both men and women. Hence, the market for nephrectomy is expected to grow in the Americas.

Europe held a substantial share in the global nephrectomy market. This can be attributed to the increasing incidence and prevalence of cancer, and public policies & reimbursement procedures in this region are expected to boost the growth of the market in this region.

Asia-Pacific is estimated to be the fastest-growing region in the global market. This is due to the increasing R&D funding by developing countries and the development of the healthcare sector.

The nephrectomy market in Rest of the World is expected to witness steady growth during the review period due to limited access and healthcare affordability among the population.

Key Players

The Prominent Players in the Global Nephrectomy Market are KARL STORZ SE & Co. KG (Germany)., Olympus Corporation (Japan), Medtronic Plc (Ireland), B. Braun Melsungen AG (Germany), Johnson & Johnson Services Inc. (US), Cook Group (US), CONMED Corporation (US), and XCELLANCE Medical Technologies (India).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nephrectomy-market-5356